• Joyce Weaver, Grenade Lois La LL, Hyon Kwon, and Mark Avigan.
• Division of Risk Management, Office of Surveillance and Epidemiology CDER, FDA, Silver Spring, Maryland 20933, USA.
• Dermatol Ther. 2009 May 1; 22 (3): 204-15.

AbstractMarketed pharmaceuticals are evaluated for safety by the US Food and Drug Administration (FDA) throughout the life cycle of the products. The FDA uses data from controlled clinical trials, from postmarketing case reports reported to the FDA's Adverse Event Reporting System, from epidemiological studies, and from registries to evaluate the safety of approved products. For some products, including some products used in dermatologic medicine, risks become apparent during the postmarketing period that require additional measures beyond product labeling and routine pharmacovigilance. The FDA continues to seek additional tools to assess risk, including pharmacogenomic biomarkers for adverse drug reactions and the use of large medical record and epidemiological databases for the systematic detection and characterization of drug-associated safety outcomes.

11 keywords...

hide…